Targeting PLA2G15 to treat neurometabolic disorders
Scenic Biotech and Stanford University have published a study identifying…
Scenic Biotech and Stanford University have published a study identifying PLA2G15 as a new drug target in neurodegenerative and metabolic diseases, potentially enabling future treatments for conditions like Niemann-Pick type C.